ARMEN GARO H

SEC source: 0001493152-26-039816 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · EXEC. CHAIR & PRINCIPAL OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,533

SEC source: 0001493152-26-039537 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · EXEC. CHAIR & PRINCIPAL OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,533

SEC source: 0001493152-26-039399 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · EXEC. CHAIR & PRINCIPAL OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,899

SEC source: 0001493152-26-037468 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · EXEC. CHAIR & PRINCIPAL OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,199

SEC source: 0001193125-26-347517 · ownership.xml · derivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,971,500

Underlying: Common Stock · 1,971,500 shares

Expires 2036-08-10

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. Amended and Restated 2019 Equity Incentive Plan. The options are divided into five equal tranches, each of which vests only if the Company's stock price achieves and sustains, for 30 consecutive calendar days during the five-year performance period, a level equal to 3x, 4x, 5x, 6x, and 8x, respectively, of the measurement price of $7.78 per share, subject in each case to a minimum three-year service requirement.

SEC source: 0001493152-26-036782 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · EXEC. CHAIR & PRINCIPAL OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,979

SEC source: 0001493152-26-036442 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · EXEC. CHAIR & PRINCIPAL OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,294

SEC source: 0001493152-26-035868 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · EXEC. CHAIR & PRINCIPAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,291

SEC source: 0001193125-26-303047 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 371,108

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 10th, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.35 is the closing price of our Common Stock on July 10th, 2026, the last trading day for the payroll date for the pay period ending July 10th, 2026.

SEC source: 0001193125-26-289278 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 366,256

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 26th, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.03 is the closing price of our Common Stock on June 26th, 2026, the last trading day for the payroll date for the pay period ending June 26th, 2026.

SEC source: 0001193125-26-271889 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 360,892

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 12th, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.30 is the closing price of our Common Stock on June 12th, 2026, the last trading day for the payroll date for the pay period ending June 12th, 2026.

SEC source: 0001193125-26-252375 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 355,967

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 29, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.50 is the closing price of our Common Stock on May 29, 2026, the last trading day for the payroll date for the pay period ending May 29, 2026.

SEC source: 0001193125-26-231046 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,323

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 15, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.58 is the closing price of our Common Stock on May 15, 2026, the last trading day for the payroll date for the pay period ending May 15, 2026.

SEC source: 0001193125-26-206908 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 346,783

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 1, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.84 is the closing price of our Common Stock on May 1, 2026, the last trading day for the payroll date for the pay period ending May 1, 2026.

SEC source: 0001193125-26-187079 · ownership.xml · derivative · entry 3

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,550

Underlying: Common Stock · 137,550 shares

Expires 2036-04-24

F2 · derivative.exercise_date: Option awarded in lieu of the 2025 annual cash bonus and in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. Vests in full on May 24, 2026.

SEC source: 0001193125-26-187079 · ownership.xml · derivative · entry 2

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,750

Underlying: Common Stock · 27,750 shares

Expires 2036-04-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027, and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001193125-26-187079 · ownership.xml · derivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000,000

Underlying: Common Stock · 1,000,000 shares

Expires 2036-04-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027, and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001193125-26-166818 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 342,550

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 17, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.79 is the closing price of our Common Stock on April 17, 2026, the last trading day for the payroll date for the pay period ending April 17, 2026.

SEC source: 0001193125-26-143765 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 339,147

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 3, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.33 is the closing price of our Common Stock on April 2, 2026, the last trading day for the payroll date for the pay period ending April 3, 2026.

SEC source: 0001193125-26-121840 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 334,518

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 20, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.71 is the closing price of our Common Stock on March 20, 2026, the last trading day for the payroll date for the pay period ending March 20, 2026.

SEC source: 0001193125-26-098528 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 330,535

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 6, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $2.96 is the closing price of our Common Stock on March 6, 2026, the last trading day for the payroll date for the pay period ending March 6, 2026.

SEC source: 0001193125-26-066948 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 325,541

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending February 20, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.06 is the closing price of our Common Stock on February 20, 2026, the last trading day for the payroll date for the pay period ending February 20, 2026.

SEC source: 0001193125-26-042772 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,712

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending February 6, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $2.94 is the closing price of our Common Stock on February 6, 2026, the last trading day for the payroll date for the pay period ending February 6, 2026.

SEC source: 0001193125-26-022561 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 315,685

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending January 23, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.24 is the closing price of our Common Stock on January 23, 2026, the last trading day for the payroll date for the pay period ending January 23, 2026.

SEC source: 0001193125-26-010360 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 311,123

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending January 9, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.91 is the closing price of our Common Stock on January 9, 2026, the last trading day for the payroll date for the pay period ending January 9, 2026.

SEC source: 0001193125-25-335288 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 307,343

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending December 26, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.31 is the closing price of our Common Stock on December 26, 2025, the last trading day for the payroll date for the pay period ending December 26, 2025.

SEC source: 0001193125-25-319186 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 302,401

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending December 12, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.79 is the closing price of our Common Stock on December 12, 2025, the last trading day for the payroll date for the pay period ending December 12, 2025.

SEC source: 0001193125-25-303859 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 298,085

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending November 28, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.56 is the closing price of our Common Stock on November 28, 2025, the last trading day for the payroll date for the pay period ending November 28, 2025.

SEC source: 0001193125-25-284600 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 294,498

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending November 14, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.34 is the closing price of our Common Stock on November 14, 2025, the last trading day for the payroll date for the pay period ending November 14, 2025.

SEC source: 0001193125-25-266875 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 290,729

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending October 31, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.97 is the closing price of our Common Stock on October 31, 2025, the last trading day for the payroll date for the pay period ending October 31, 2025.

SEC source: 0001193125-25-245089 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 286,609

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending October 17, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.88 is the closing price of our Common Stock on October 17, 2025, the last trading day for the payroll date for the pay period ending October 17, 2025.

SEC source: 0001193125-25-231857 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 282,393

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending October 3, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.14 is the closing price of our Common Stock on October 3, 2025, the last trading day for the payroll date for the pay period ending October 3, 2025.

SEC source: 0001193125-25-213291 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 278,442

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending September 19, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.38 is the closing price of our Common Stock on September 19, 2025, the last trading day for the payroll date for the pay period ending September 19, 2025.

SEC source: 0001193125-25-199162 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 274,708

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending September 5, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.33 is the closing price of our Common Stock on September 5, 2025, the last trading day for the payroll date for the pay period ending September 5, 2025.

SEC source: 0000950170-25-111446 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 270,930

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending August 22, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.52 is the closing price of our Common Stock on August 22, 2025, the last trading day for the payroll date for the pay period ending August 22, 2025.

SEC source: 0000950170-25-106531 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 267,311

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending August 8, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.80 is the closing price of our Common Stock on August 8, 2025, the last trading day for the payroll date for the pay period ending August 8, 2025.

SEC source: 0000950170-25-099156 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 263,904

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 25, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $5.96 is the closing price of our Common Stock on July 25, 2025, the last trading day for the payroll date for the pay period ending July 25, 2025.

SEC source: 0000950170-25-095868 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 261,159

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 11, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $7.06 is the closing price of our Common Stock on July 11, 2025, the last trading day for the payroll date for the pay period ending July 11, 2025.

SEC source: 0000950170-25-091637 · ownership.xml · nonDerivative · entry 2

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 258,842

F3 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 27, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F4 · price: $4.76 is the closing price of our Common Stock on June 27, 2025, the last trading day for the payroll date for the pay period ending June 27, 2025.

SEC source: 0000950170-25-091637 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 255,406

F1 · security: Reflects the executive's 2024 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a 30-day lockup restriction with 100% of the award released on July 18, 2025.

F2 · price: $4.47 was the fair market value of Agenus Common Stock on June 18, 2025, the stock issuance date.

SEC source: 0000950170-25-088492 · ownership.xml · derivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2035-05-28

F1 · derivative.exercise_date: Options were granted on May 28, 2025 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 17, 2025. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on May 28, 2026 and the balance vesting in equal quarterly installments thereafter.

SEC source: 0000950170-25-087378 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194,009

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 13, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.70 is the closing price of our Common Stock on June 13, 2025, the last trading day for the payroll date for the pay period ending June 13, 2025.

SEC source: 0000950170-25-080903 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,529

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 30, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.43 is the closing price of our Common Stock on May 30, 2025, the last trading day for the payroll date for the pay period ending May 30, 2025.

SEC source: 0000950170-25-075159 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,750

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 16, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.48 is the closing price of our Common Stock on May 16, 2025, the last trading day for the payroll date for the pay period ending May 16, 2025.

SEC source: 0000950170-25-063521 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 181,060

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 2, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.11 is the closing price of our Common Stock on May 2, 2025, the last trading day for the payroll date for the pay period ending May 2, 2025.

SEC source: 0000950170-25-056720 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,800

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 18, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $2.08 is the closing price of our Common Stock on April 17, 2025, the last trading day for the payroll date for the pay period ending April 18, 2025.

SEC source: 0000950170-25-052051 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,914

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 4, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $1.56 is the closing price of our Common Stock on April 4, 2025, the payroll date for the pay period ending April 4, 2025.

SEC source: 0000950170-25-043816 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,626

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 21, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $1.61 is the closing price of our Common Stock on March 21, 2025, the payroll date for the pay period ending March 21, 2025.

SEC source: 0000950170-25-037126 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,383

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 7, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $2.35 is the closing price of our Common Stock on March 7, 2025, the payroll date for the pay period ending March 7, 2025.

SEC source: 0000950170-25-026617 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,051

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending February 21, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.32 is the closing price of our Common Stock on February 21, 2025, the payroll date for the pay period ending February 21, 2025.